

# Building the National Evaluation System for Medical Devices: Using Real-World Evidence to Improve Device Safety and Effectiveness

## PCORnet Perspective

*W. Schuyler Jones, MD*

*Division of Cardiology, Duke University*

*March 24, 2016*



**pcornet**


The National Patient-Centered Clinical Research Network

# PCORnet: the National Patient-Centered Clinical Research Network



PCORnet's goal is to **improve the nation's capacity to conduct CER efficiently, by creating a large, highly representative, national patient-centered clinical research network** for conducting clinical outcomes research.

The vision is to support a learning US healthcare system, which would allow for **large-scale research** to be conducted with **enhanced accuracy and efficiency**.



# Overarching Objective of PCORnet: Develop a single functional research network

**Create** infrastructure, tools, and policies to support rapid, efficient comparative effectiveness research

**Utilize** multiple electronic health records, insurance claims data, data reported directly by patients, and other data sources

**Engage** patients, clinicians, and health system leaders throughout

# PCORnet as Part of a National Evidence Generation Infrastructure

## Medical Product Safety Surveillance

### FDA

↓

Sentinel  
Coordinating  
Center

Coordinating  
Center(s)

↑

FDA, Industry

## Medical Product Safety

Coordinating  
Center(s)

↑

NIH, Industry

## Clinical Research

DISTRIBUTED NETWORK GOVERNANCE

**Sentinel**

- Payers
  - Public
  - Private

**PCORnet**



• Providers

- Hospitals
- Physicians
- Integrated Systems

• Registries

- Disease-specific
- Product-specific

Common  
Data Model

- Data Standards

Coordinating  
Center(s)

↑

PCORI, NIH, Industry

## Comparative Effectiveness Research

## Quality of Care

Health Plans, others

↓

Coordinating  
Center(s)


Coordinating  
Center(s)

↑

Sponsor(s)

## Public Health Surveillance

CDC



# PCORnet Common Data Model v3.0

New to v3.0

## DEMOGRAPHIC

**PATID**  
BIRTH\_DATE  
BIRTH\_TIME  
SEX  
HISPANIC  
RACE  
BIOBANK\_FLAG

Fundamental basis

## ENROLLMENT

**PATID**  
**ENR\_START\_DATE**  
ENR\_END\_DATE  
CHART  
**ENR\_BASIS**

## DISPENSING

**DISPENSINGID**  
**PATID**  
PRESCRIBINGID (optional)  
**DISPENSE\_DATE**  
NDC  
DISPENSE\_SUP  
DISPENSE\_AMT

## DEATH

**PATID**  
**DEATH\_DATE**  
DEATH\_DATE\_IMPUTE  
**DEATH\_SOURCE**  
DEATH\_MATCH\_CONFIDENCE

## DEATH\_CONDITION

**PATID**  
**DEATH\_CAUSE**  
**DEATH\_CAUSE\_CODE**  
**DEATH\_CAUSE\_TYPE**  
**DEATH\_CAUSE\_SOURCE**  
DEATH\_CAUSE\_CONFIDENCE

Data captured from processes associated with healthcare delivery

## VITAL

**VITALID**  
**PATID**  
ENCOUNTERID (optional)  
**MEASURE\_DATE**  
MEASURE\_TIME  
**VITAL\_SOURCE**  
HT  
WT  
DIASTOLIC  
SYSTOLIC  
ORIGINAL\_BMI  
BP\_POSITION  
**SMOKING**  
TOBACCO  
TOBACCO\_TYPE

## CONDITION

**CONDITIONID**  
**PATID**  
ENCOUNTERID (optional)  
REPORT\_DATE  
RESOLVE\_DATE  
**ONSET\_DATE**  
CONDITION\_STATUS  
**CONDITION**  
**CONDITION\_TYPE**  
**CONDITION\_SOURCE**

## PRO\_CM

**PRO\_CM\_ID**  
**PATID**  
ENCOUNTERID (optional)  
**PRO\_ITEM**  
PRO\_LOINC  
**PRO\_DATE**  
PRO\_TIME  
**PRO\_RESPONSE**  
PRO\_METHOD  
PRO\_MODE  
PRO\_CAT

Data captured within multiple contexts: healthcare delivery, registry activity, or directly from patients

## ENCOUNTER

**ENCOUNTERID**  
**PATID**  
**ADMIT\_DATE**  
ADMIT\_TIME  
DISCHARGE\_DATE  
DISCHARGE\_TIME  
PROVIDERID  
FACILITY\_LOCATION  
**ENC\_TYPE**  
FACILITYID  
DISCHARGE\_DISPOSITION  
DISCHARGE\_STATUS  
DRG  
DRG\_TYPE  
ADMITTING\_SOURCE

## DIAGNOSIS

**DIAGNOSISID**  
**PATID**  
**ENCOUNTERID**  
*ENC\_TYPE (replicated)*  
*ADMIT\_DATE (replicated)*  
*PROVIDERID (replicated)*  
**DX**  
**DX\_TYPE**  
**DX\_SOURCE**  
PDX

## PROCEDURES

**PROCEDURESID**  
**PATID**  
**ENCOUNTERID**  
*ENC\_TYPE (replicated)*  
*ADMIT\_DATE (replicated)*  
*PROVIDERID (replicated)*  
PX\_DATE  
**PX**  
**PX\_TYPE**  
PX\_SOURCE

Data captured from healthcare delivery, direct encounter basis

## LAB\_RESULT\_CM

**LAB\_RESULT\_CM\_ID**  
**PATID**  
ENCOUNTERID (optional)  
LAB\_NAME  
SPECIMEN\_SOURCE  
LAB\_LOINC  
PRIORITY  
RESULT\_LOC  
LAB\_PX  
LAB\_PX\_TYPE  
LAB\_ORDER\_DATE  
SPECIMEN\_DATE  
SPECIMEN\_TIME  
**RESULT\_DATE**  
RESULT\_TIME  
RESULT\_QUAL  
RESULT\_NUM  
RESULT\_MODIFIER  
RESULT\_UNIT  
NORM\_RANGE\_LOW  
NORM\_MODIFIER\_LOW  
NORM\_RANGE\_HIGH  
NORM\_MODIFIER\_HIGH  
ABN\_IND

## PRESCRIBING

**PRESCRIBINGID**  
**PATID**  
ENCOUNTERID (optional)  
RX\_PROVIDERID  
RX\_ORDER\_DATE  
RX\_ORDER\_TIME  
RX\_START\_DATE  
RX\_END\_DATE  
RX\_QUANTITY  
RX\_REFILLS  
RX\_DAYS\_SUPPLY  
RX\_FREQUENCY  
RX\_BASIS  
RXNORM\_CUI

## PCORNET\_TRIAL

**PATID**  
**TRIALID**  
**PARTICIPANTID**  
TRIAL\_SITEID  
TRIAL\_ENROLL\_DATE  
TRIAL\_END\_DATE  
TRIAL\_WITHDRAW\_DATE  
TRIAL\_INVITE\_CODE

Associations with PCORnet clinical trials

## HARVEST

**NETWORKID**  
NETWORK\_NAME  
**DATAMARTID**  
DATAMART\_NAME  
DATAMART\_PLATFORM  
CDM\_VERSION  
DATAMART\_CLAIMS  
DATAMART\_EHR  
BIRTH\_DATE\_MGMT  
ENR\_START\_DATE\_MGMT  
ENR\_END\_DATE\_MGMT  
DISCHARGE\_DATE\_MGMT  
PX\_DATE\_MGMT  
RX\_ORDER\_DATE\_MGMT  
RX\_START\_DATE\_MGMT  
RX\_END\_DATE\_MGMT  
DISPENSE\_DATE\_MGMT  
LAB\_ORDER\_DATE\_MGMT  
SPECIMEN\_DATE\_MGMT  
RESULT\_DATE\_MGMT  
MEASURE\_DATE\_MGMT  
ONSET\_DATE\_MGMT  
REPORT\_DATE\_MGMT  
RESOLVE\_DATE\_MGMT  
PRO\_DATE\_MGMT  
REFRESH\_DEMOGRAPHIC\_DATE  
REFRESH\_ENROLLMENT\_DATE  
REFRESH\_ENCOUNTER\_DATE  
REFRESH\_DIAGNOSIS\_DATE  
REFRESH\_PROCEDURES\_DATE  
REFRESH\_VITAL\_DATE  
REFRESH\_DISPENSING\_DATE  
REFRESH\_LAB\_RESULT\_CM\_DATE  
REFRESH\_CONDITION\_DATE  
REFRESH\_PRO\_CM\_DATE  
REFRESH\_PRESCRIBING\_DATE  
REFRESH\_PCORNET\_TRIAL\_DATE  
REFRESH\_DEATH\_DATE  
REFRESH\_DEATH\_CAUSE\_DATE

Process-related data

<http://www.pcornet.org/resource-center/pcornet-common-data-model/>

Bold font indicates fields that cannot be null due to primary key definitions or record-level constraints.



The PCORnet CDM lives at

<http://pcornet.org/pcornet-common-data-model/>

# PCORnet Research Readiness: Data Infrastructure

## Clinical Data Research Networks

- 13 networks with  $\geq 1$  million patients into PCORnet Common Data Model (CDM)

## Patient data available in PCORnet DataMarts to date:


**~75 Million**





# PCORnet People Power: transforming clinical research through the PPRNs

- 🌐 Patient Powered Research Networks represent 20 different models of partnerships and infrastructure, representing over 100 diseases overall



# Many parts of PCORnet are still under construction





# Short- and Long-Term Outcomes related to Bariatric Surgery



**pcornet**

The National Patient-Centered Clinical Research Network

# Short- and Long-Term Effects of Antibiotics on Childhood Growth



**pcornet**

The National Patient-Centered Clinical Research Network

# Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

*PCORnet's First Pragmatic Clinical Trial*




**pcornet**

The National Patient-Centered Clinical Research Network

# Open science

- Protocol and survey questions posted for public review and comment in July 2015
- Public and CDRN feedback contributed to key protocol changes
  - Exclusion of ticagrelor-treated patients
  - Exclusion of patients with potential indications for an oral anticoagulant, even if not treated with one
  - Inclusion of patients regardless of prior use of aspirin before randomization
- All ADAPTABLE materials and information are posted publicly (<http://theaspirinstudy.org>)
- Open dissemination plan for trial results

# Patient Engagement in All Trial Aspects




# ADAPTABLE Study Design

**Patients with known ASCVD +  $\geq 1$  “enrichment factor”\***

Identified through EHR (computable phenotype) by CDRNs  
(PPRN patients that are already a part of a CDRN are eligible to participate.)



# Computable phenotype for CDRNs



# ADAPTABLE Study Design

## **Patients with known ASCVD + $\geq 1$ “enrichment factor”\***

Identified through EHR (computable phenotype) by CDRNs  
(PPRN patients that are already a part of a CDRN are eligible to participate.)



Patients contacted with trial information and link to e-consent;<sup>†</sup>  
Treatment assignment will be provided directly to patient



Patients meeting eligibility

*Managed at site and/or network level*  
***This is where the phenotype is situated***

Patients who are invited

Patients who visit portal

*The patient answers a few basic questions to **check for those unsafe to participate**, but full eligibility criteria was determined at the site level*


Patients who choose  
to participate

**Patients Enrolled  
in ADAPTABLE**

## Golden Ticket (Invite)



## ADAPTABLE Subject ID





# Adaptable

The Aspirin Study

Presented in English

[En Español](#)

A TEXT SIZE A

## Let's get started!

Thank you for taking the time to find out more details about the ADAPTABLE aspirin study. With your help, we hope to find out what is the right dose of aspirin for people with heart disease.

### Got a code?

Please enter in the special code that was included in your invitation:

AX3BN

ENTER



### No code? No problem!

You can still learn more about this study even if you have not been asked to participate.



CONTINUE

Already have a profile? [Login](#)



Adaptable



pcornet

POWERED BY



mytrus.

[Contact Us](#) [Help](#)

© Mytrus, Inc., 2016 - All Rights Reserved



# Adaptable

The Aspirin Study

A TEXT SIZE A

## There are 5 steps to join the study!

The time on each card is an estimate of  
how long it will take you to complete each section.

**There are no time limits, so please go at your own pace.**

<b>Watch</b> the ADAPTABLE short video	<b>Read</b> more details about participating in ADAPTABLE	<b>Answer</b> a few questions about the study	<b>Join</b> the ADAPTABLE study	<b>Inform</b> us about your current health
5 min	15 min	5 min	3 min	5 min



LET'S GET STARTED



# ADAPTABLE Study Design

## Patients with known ASCVD + $\geq 1$ “enrichment factor”\*

Identified through EHR (computable phenotype) by CDRNs  
(PPRN patients that are already a part of a CDRN are eligible to participate.)

Patients contacted with trial information and link to e-consent;<sup>†</sup>  
Treatment assignment will be provided directly to patient

ASA 81 mg QD

ASA 325 mg QD

Electronic follow-up: Every 3–6 months  
Supplemented with EHR/CDM/claims data

**Duration:** Enrollment over 24 months;  
maximum follow-up of 30 months

<sup>†</sup> Participants without internet access may be consented and followed via a parallel system.

# ADAPTABLE Study Design

## Patients with known ASCVD + $\geq 1$ “enrichment factor”\*

Identified through EHR (computable phenotype) by CDRNs  
(PPRN patients that are already a part of a CDRN are eligible to participate.)

Patients contacted with trial information and link to e-consent;<sup>†</sup>  
Treatment assignment will be provided directly to patient

### Exclusion criteria

- Age <18 years
- ASA allergy or contraindication (including pregnancy or nursing)
- Significant GI bleed within past 12 months
- Significant bleeding disorder
- Requires warfarin, direct oral anticoagulant, or ticagrelor

ASA 81 mg QD

ASA 325 mg QD

Electronic follow-up: Every 3–6 months  
Supplemented with EHR/CDM/claims data

**Duration:** Enrollment over 24 months;  
maximum follow-up of 30 months

### \*Enrichment factors

- Age >65 years
- Creatinine >1.5 mg/dL
- Diabetes mellitus (type 1 or 2)
- Known 3-vessel CAD
- Current CVD or PAD
- Known EF <50% by echo, cath, nuclear study
- Current smoker

### Primary endpoint:

Composite of all-cause mortality, hospitalization for MI, or hospitalization for stroke

### Primary safety endpoint:

Hospitalization for major bleeding

<sup>†</sup> A subset of participants who do not have internet access may be consented and followed via a parallel system.

# Enabling and testing pragmatic research: e-data collection and e-follow-up

N=20,000



ADAPTABLE  
enrollee



Baseline data

## Web portal follow-up

- Randomized to 3 vs 6 mos contact
- Patient-reported hospitalizations
- Medication use
- Health outcomes



## DCRI call center

- *Contacts patients who miss 2 e-visits*
- *Collect identical data by phone*



## PCORnet Coordinating Center follow-up

- Via Common Data Model
- Validated coding algorithms for endpoints



## CMS and private health plans follow-up

- Longitudinal health outcomes
- Validated coding algorithms for endpoints









## Death ascertainment

National Death  
Index (NDI) &  
Social Security  
Database


## Hi, Allison! Welcome back.

Please complete each form. The time on each card is an estimate of how long it will take you to complete each section.

**There are no time limits, so please go at your own pace.**

			
<b>Info</b> Contact & insurance information	<b>History</b> Past history	<b>Medications</b> Have your current medications handy	<b>Hospitalization</b> Let us know about any hospitalizations
 5 min	 5 min	 5 min	 3 min

LET'S GET STARTED



### Your assigned aspirin dosage

You have been assigned the daily dosage of **325 mg** of aspirin each day for participation in the ADAPTABLE study.

[Re-watch video](#) | [Re-read documents](#)

# Cost

- ADAPTABLE: **\$850** per participant
  - 20,000 participants
  - \$17M total cost
- PROMISE\* (pragmatic trial): **\$3,100** per participant
  - 10,003 participants
  - \$27M total cost
- BRIDGE\*\*: **\$13,000** per participant
  - 1,884 participants
  - \$23M total cost

\*Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease  
<http://www.nejm.org/doi/full/10.1056/NEJMoa1415516>

\*\*Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation  
<http://www.nejm.org/doi/full/10.1056/NEJMoa1501035>

# Learn more about ADAPTABLE

---

 <http://theaspirinstudy.org>



## PCORnet's Top 5 Needs:

---

- ✓ Engaged clinical organizations and patients
- ✓ Collaboration framework
- ✓ Analysis-ready standardized data with strong privacy protections
- ☐ Ability to embed research in care settings (clinicians *required*)
- ☐ Regulatory oversight that protects patients without unnecessary burdens

Thanks!

